Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7471512 | 0.80 | SRD5A2 (0.36) | TSHRSRC | |
| SCHEMBL1005299 | 0.79 | — | — | |
| SCHEMBL11124101 | 0.77 | SRC (0.34) | TSHRSRC | |
| SCHEMBL4896034 | 0.77 | ADRA2A (0.40) | — | |
| SCHEMBL3326062 | 0.77 | SRC (0.30) | SRC | |
| SCHEMBL10497076 | 0.77 | CES2 (0.32) | SRC | |
| SCHEMBL9532661 | 0.76 | — | — | |
| SCHEMBL2458784 | 0.76 | — | — | |
| SCHEMBL1472929 | 0.76 | — | — | |
| SCHEMBL7461974 | 0.75 | IDO1 (0.51) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | claimed |
| EP-2007373-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | Foldrx Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| WO-2023168077-A1 | PHENOL-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE | CONAGEN INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2019113085-A1 | ELECTROCHEMICAL DETECTION SYSTEMS AND COMPONENTS THEREOF | Laxmi Therapeutic Devices, Inc. (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-3191500-A2 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS | Academia Sinica (TW) | 2017-07-19 | — | — | EP | disclosed |
| EP-3052134-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2016040369-A2 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS | ACADEMIA SINICA (TW) | 2016-03-17 | — | — | WO | disclosed |
| EP-2935242-A2 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2892510-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2892512-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1575486-A4 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753713-A2 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | The President and Fellows of Harvard College (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1620445-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005112945-A2 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1575486-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005044279-A1 | PURINE NUCLEOSIDE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004096818-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | TSHR 4299/4885SRC 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.